A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 720
- Registration Number
- NCT06142383
- Locations
- 🇺🇸
SEC Clinical Research Research, Dothan, Alabama, United States
🇺🇸Heart Center Research Llc ., Huntsville, Alabama, United States
🇺🇸Pima Heart And Vascular Clin Rch Research, Tucson, Arizona, United States
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06133972
- Locations
- 🇺🇸
Pinnacle Research Group Llc, Anniston, Alabama, United States
🇺🇸Millennium Clinical Trials, Westlake Village, California, United States
🇺🇸Clinical Res Of W Florida, Clearwater, Florida, United States
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT06130540
- Locations
- 🇺🇸
Houston Rheumatology & Arthrit, Katy, Texas, United States
🇺🇸Accurate Clinical Research Inc, San Antonio, Texas, United States
🇺🇸Overlake Internal Med Associates, Bellevue, Washington, United States
WOE of Anti-CD20 Therapies
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06121349
- Locations
- 🇺🇸
Novartis Investigational site, East Hanover, New Jersey, United States
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT06097663
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Vanderbilt University Medical Cent, Nashville, Tennessee, United States
🇩🇪Novartis Investigative Site, Muenchen, Germany
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT06092879
- Locations
- 🇫🇷
Novartis Investigative Site, Strasbourg cedex, France
A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT06075758
- Locations
- 🇯🇴
Novartis Investigative Site, Amman, Jordan
A Real-world Study to Assess Safety and Effectiveness of Xolair® in Pediatric Chronic Spontaneous Urticaria in China
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 59
- Registration Number
- NCT06053801
- Locations
- 🇨🇳
Novartis Investigative Site, Shanghai, China
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 468
- Registration Number
- NCT06042478
- Locations
- 🇻🇳
Novartis Investigative Site, Hanoi, Vietnam
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT06031844
- Locations
- 🇺🇸
Valley Clinical Trials CPRT128A2302, Northridge, California, United States
🇺🇸Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States
🇺🇸University of Florida Health Science Center UF Health Jacksonville, Jacksonville, Florida, United States